On July 8, 2026, Rhythm Pharmaceuticals, Inc. revealed that data from its Phase 3 TRANSCEND study on setmelanotide for acquired hypothalamic obesity patients is now available in The New England Journal of Medicine. Rhythm Pharmaceuticals, a Nasdaq-listed company (RYTM), specializes in rare neuroendocrine disease treatments. The trial focused on setmelanotide, an MC4R agonist, and its efficacy. The publication signifies a significant milestone for the global biopharmaceutical company, highlighting their dedication to improving the lives of those with rare conditions.